Company intelligence / Profile preview

JeniVision

Ownership: Private
Development stage: Phase 2

Overview

JeniVision has multiple programs in development, with at least one drug (JV-HG1 for hair diseases) in clinical trials. Their dry eye medication is designed to relieve and reverse pain, while their anti-glaucoma agent is reported to be more effective and long-acting than available drugs with a new delivery route that's more convenient than conventional eye drops.

Therapeutic areas: OphthalmologyDermatology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

PGN 9856-isopropyl ester

Beyond the preview

Go deeper on JeniVision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JeniVision.

Explore the full profile